Humanin vs Pinealon
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
- Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
- Half-Life
- ~4–8 hours (HNG)
- Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
- Admin Route
- SubQ
- SubQ, Oral, Intranasal
- Research
- —
- —
- Typical Dose
- 2–8 mg
- 5–10 mg (oral) or 50–100 mcg (SC)
- Frequency
- 3–5 times per week
- Once daily for 10 days
- Key Benefits
- Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
- Inhibits cellular apoptosis
- Improves insulin sensitivity
- Reduces cardiovascular risk markers
- Anti-inflammatory effects
- Correlates with longevity in centenarian studies
- Protects against ischemic injury
- Potential cancer cell apoptosis sensitization
- Neuroprotection against oxidative stress and hypoxia
- Promotes neuronal regeneration and repair
- Improves memory and cognitive function
- Enhances sleep quality via melatonin regulation
- Anti-aging effects on brain cells
- May slow cognitive decline in neurodegeneration
- Improves cerebrovascular circulation
- Reduces neuroinflammation
- Side Effects
- Injection site irritation
- Limited human safety data available
- Excellent safety profile in clinical use
- Rare: mild drowsiness
- Transient mild headache at initiation
- Injection site reaction (SC)
- Stacks With
- —
- —